Ann: MND Biomarkers and Pharmacodynamics Results, page-127

You've alerted me to similar thoughts!
Everything may move faster as the data develops, so MND now, Parkinson next, Covid soon and other viruses next, Cancer for main issue, then other cancers.
Each year, they could commercialise based on their 8o+ patents with a new solution every year or less, and licencing with each.
They could be starting from Phase Two with most solutions, given current data, and may also have options for further FDA fast tracking depending on the solution and need, especially with further Neurological needs.
This would be in the future, however could keep PAA busy for may years to come, as this Monapantel compound is looking good for many health issues. Can't wait to see if they can move faster as this data develops.
The options in the money and licencing out K9 cancer will assist fast tracking by providing financing for additional resources......
Sorry, 2 glasses of wine and i get too excited!